Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis
© The Author(s) 2020. Published by Oxford University Press..
Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but some patients suffer from immune-related adverse events during or after ICI treatments. The monoclonal antibody infliximab is usually chosen as a salvage treatment to combat corticosteroid-resistant adverse events, but infliximab is not recommended as a response to hepatitis because of the potential risk of liver failure. An alternative treatment option has not been established. We treated a head and neck cancer patient (a 50-year-old Japanese male) who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2020 |
---|---|
Enthalten in: |
Oxford medical case reports - 2020(2020), 4 vom: 31. Apr., Seite omaa027 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nakano, Kenji [VerfasserIn] |
---|
Links: |
---|
Themen: |
Head and neck cancer |
---|
Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1093/omcr/omaa027 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310580080 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310580080 | ||
003 | DE-627 | ||
005 | 20231225140414.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/omcr/omaa027 |2 doi | |
028 | 5 | 2 | |a pubmed24n1035.xml |
035 | |a (DE-627)NLM310580080 | ||
035 | |a (NLM)32477577 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nakano, Kenji |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.09.2020 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © The Author(s) 2020. Published by Oxford University Press. | ||
520 | |a Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but some patients suffer from immune-related adverse events during or after ICI treatments. The monoclonal antibody infliximab is usually chosen as a salvage treatment to combat corticosteroid-resistant adverse events, but infliximab is not recommended as a response to hepatitis because of the potential risk of liver failure. An alternative treatment option has not been established. We treated a head and neck cancer patient (a 50-year-old Japanese male) who suffered from corticosteroid-resistant hepatitis during treatment with nivolumab, an anti-PD-1 ICI, and that was recovered by mycophenolate mofetil salvage therapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a head and neck cancer | |
650 | 4 | |a immune-related adverse event | |
650 | 4 | |a mycophenolate | |
650 | 4 | |a nivolumab | |
700 | 1 | |a Nishizawa, Masatoshi |e verfasserin |4 aut | |
700 | 1 | |a Fukuda, Naoki |e verfasserin |4 aut | |
700 | 1 | |a Urasaki, Tetsuya |e verfasserin |4 aut | |
700 | 1 | |a Wang, Xiaofei |e verfasserin |4 aut | |
700 | 1 | |a Mitani, Hiroki |e verfasserin |4 aut | |
700 | 1 | |a Takahashi, Shunji |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Oxford medical case reports |d 2014 |g 2020(2020), 4 vom: 31. Apr., Seite omaa027 |w (DE-627)NLM249148072 |x 2053-8855 |7 nnns |
773 | 1 | 8 | |g volume:2020 |g year:2020 |g number:4 |g day:31 |g month:04 |g pages:omaa027 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/omcr/omaa027 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 2020 |j 2020 |e 4 |b 31 |c 04 |h omaa027 |